Despite major advances in cancer research and treatment, healthcare inequality remains a serious issue. A recent study highlights that racial disparities in lung cancer treatment continue to affect patient outcomes in the United States. Researchers found that Black patients with early-stage lung cancer are still less likely to receive potentially curative treatments compared to white patients.
This gap has existed for decades and has shown little improvement, raising concerns among medical experts and policymakers. Understanding why these disparities occur is essential for improving access to life-saving care.
This article explores the findings of the study, why these differences in treatment exist, and what changes experts believe are necessary to close the gap.
Researchers analyzed treatment patterns among more than 28,000 Medicare beneficiaries diagnosed with early-stage non-small cell lung cancer between 2005 and 2019. The findings were published in JAMA Network Open in March 2026.
Even though all patients included in the study had Medicare coverage, which removes insurance status as a major barrier, significant differences in treatment remained.
The study focused on two key treatment options often used to cure early-stage lung cancer:
Both approaches can significantly improve survival when the cancer is detected early.
However, the results revealed a consistent pattern. Black patients were less likely than white patients to receive these potentially curative treatments.
One of the clearest disparities appeared in surgical treatment rates.
Between 2005 and 2007:
More than a decade later, the difference remained.
Between 2015 and 2017:
While surgery rates decreased overall due to the introduction of alternative treatments, the racial treatment gap persisted.
Experts say this pattern suggests that improvements in medical technology alone are not enough to eliminate healthcare inequality.
Researchers believe the disparity may stem from unequal access to healthcare resources rather than differences in medical recommendations.
Once Black patients reached surgeons and were evaluated for treatment, they were just as likely as white patients to receive procedures recommended by clinical guidelines.
This suggests that the problem occurs earlier in the care process.
Possible barriers include:
Healthcare researchers believe that improving access to specialized care could help reduce these disparities.
The study also examined the rollout of a newer treatment known as stereotactic body radiation therapy (SBRT).
SBRT is a highly precise form of radiation that delivers intense doses directly to tumors while minimizing damage to surrounding tissue. It became widely available in the early 2010s and is often used for patients who cannot undergo surgery.
However, the study found that Black patients were less likely to receive SBRT when it was first introduced.
Over time, access to SBRT improved for Black patients as the technology became more widely distributed. But during its early adoption period, disparities increased.
This pattern highlights an important issue in healthcare innovation. When new treatments become available, they often appear first in well-funded hospitals and specialized centers. Communities with fewer healthcare resources may receive access later.
As a result, medical advances can unintentionally increase healthcare inequality if access is not carefully managed.
Over the past 30 years, lung cancer research has made major strides.
Advances include:
These innovations have significantly improved survival rates for many lung cancer patients.
However, experts emphasize that progress in medicine must reach all populations to truly improve public health.
If certain groups consistently receive fewer treatments or delayed care, overall progress in cancer outcomes will remain uneven.
Several complex factors contribute to ongoing racial disparities in healthcare.
Access to specialized cancer treatment centers varies widely between regions. Hospitals in underserved communities may lack advanced equipment or specialists.
Patients often rely on primary care physicians to refer them to specialists. Differences in referral patterns can influence whether patients receive surgery or advanced therapies.
Transportation challenges, appointment availability, and distance to major hospitals can all limit access to treatment.
Decades of social and economic inequality continue to influence healthcare access today.
Some patients may not receive full information about treatment options or clinical trials, which can affect decision-making.
Researchers emphasize that addressing these issues requires systemic changes rather than focusing only on individual patient behavior.
Early-stage lung cancer is often treatable and sometimes curable if treated promptly.
Surgery and targeted radiation therapies are considered standard treatments because they can remove or destroy tumors before the cancer spreads.
Patients who receive these treatments often have significantly better survival outcomes compared to those who receive only palliative care.
Because of this, differences in access to curative treatments can directly impact survival rates across populations.
Ensuring equal access to these therapies is a major priority for public health experts.
Researchers say documenting disparities is only the first step. The next challenge is identifying effective solutions.
Potential strategies include:
Increasing the number of cancer treatment centers in underserved areas could improve access to surgery and advanced therapies.
Healthcare systems can develop protocols that ensure all eligible patients are referred to specialists for evaluation.
Hospitals and healthcare networks may need to track treatment patterns to identify disparities and address them quickly.
Educational programs can help patients understand available treatment options and encourage early screening.
Patient navigation programs help individuals coordinate appointments, transportation, and follow-up care.
These initiatives can reduce barriers that prevent patients from receiving timely treatment.
Researchers say additional studies are needed to better understand the causes of treatment disparities.
Future research may examine:
Understanding these factors can help healthcare leaders design targeted policies to close treatment gaps.
The new findings highlight a critical reality. Medical innovation alone cannot solve healthcare inequality.
While lung cancer treatment has improved dramatically over the past few decades, those benefits have not been distributed equally.
Experts stress that progress in medicine must be accompanied by progress in healthcare access. Ensuring that all patients receive appropriate care requires collaboration among hospitals, policymakers, researchers, and communities.
Addressing disparities in cancer treatment could significantly improve outcomes for thousands of patients each year.
The study published in JAMA Network Open provides important insight into ongoing racial disparities in lung cancer treatment. Despite decades of progress in cancer research, Black patients remain less likely to receive surgery or radiation therapy intended to cure early-stage lung cancer.
Because the study focused on Medicare beneficiaries, the findings suggest that insurance coverage alone does not eliminate treatment gaps.
Experts believe the disparities may stem from differences in access to specialized care, referral systems, and healthcare infrastructure.
Recognizing these issues is a crucial step toward building a more equitable healthcare system. Continued research and targeted policy changes will be necessary to ensure that life-saving cancer treatments reach every patient who needs them.
This article is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Medical information presented here reflects general research findings and may not apply to every individual. Always consult a qualified healthcare professional regarding medical conditions, treatment decisions, or health concerns.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.